The table below shows Mineralys Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Operating cash flow
-$39.47M
-$45.49M
-$19.14M
-$12.78M
-$6.58M
Capital expenditure
-
-
-
-
-
Investing cash flow
-$44.94M
-$92.88M
-$55.95M
-$140.25M
$0.00
Dividends paid
-
-
-
-
-
Stock buybacks
-
-
MLYS operating cash flow (10-K history)
Mineralys Therapeutics, Inc. reported operating cash flow of -$142.42M for fiscal year 2025. That is up 14.4% from -$166.31M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.